Trials / Completed
CompletedNCT03218241
Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote
A Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered PRT064445, a Factor Xa (fXa) Inhibitor Antidote
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Portola Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is a single center, double-blind, randomized, placebo-controlled, ascending, single dose study of PRT064445 or its matching placebo, in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PRT064445 | Intravenous |
| DRUG | Placebo | Intravenous to mimic PRT064445 |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2012-09-01
- Completion
- 2012-10-01
- First posted
- 2017-07-14
- Last updated
- 2023-08-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03218241. Inclusion in this directory is not an endorsement.